Literature DB >> 30712041

Reported Outcomes in Perinatal Iron Deficiency Anemia Trials: A Systematic Review.

Ann Kinga Malinowski1,2,3, Rohan D'Souza4,5,6, Khalid S Khan7, Nadine Shehata5,8,9, Marcin Malinowski4, Jahnavi Daru7.   

Abstract

BACKGROUND/AIMS: Iron deficiency (ID) and iron deficiency anemia (IDA) are global health concerns associated with adverse perinatal effects. Despite efforts taken at the international level, there is no consensus on unified prevention/treatment strategies, largely stemming from inconsistencies of outcome reporting. Our objective was to comprehensively assess outcome reporting perinatal iron intervention trials as Phase 1 of core outcome set (COS) development to inform future research.
METHODS: Systematic search in MEDLINE, EMBASE, Cochrane Databases, and CINAHL (January 2000 - April 2016), with inclusion of trials involving pregnant or postpartum women with ID/IDA confirmed before recruitment. Articles were independently screened and selected by 2 reviewers; data were extracted in duplicate. Quality was assessed using published scoring systems. Outcome definitions and measurement methods were tabulated.
RESULTS: Of 7,046 citations, 33 randomized controlled trials were included. Sixty-nine reported outcomes were categorized into 8 domains. High methodological quality characterized 25 (76%) studies. Reporting quality was low in 16 (49%), moderate in 13 (39%), and high in 4 (12%) studies. Variation was greatest for outcome definition, timing of assessment and measurement methods.
CONCLUSION: This review identifies a comprehensive long-list of outcomes reported of perinatal iron interventions for ID/IDA. Beyond highlighting existing variation in outcome reporting, it provides a foundation for development of a COS for future trials.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Antepartum; Core outcome set; Data harmonization; Iron deficiency; Iron deficiency anemia; Outcome reporting; Postpartum; Pregnancy

Mesh:

Substances:

Year:  2019        PMID: 30712041     DOI: 10.1159/000495566

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  6 in total

1.  Intravenous ferric derisomaltose versus oral iron for persistent iron deficient pregnant women: a randomised controlled trial.

Authors:  Rebecka Hansen; Veronika Markova Sommer; Anja Pinborg; Lone Krebs; Lars Lykke Thomsen; Torben Moos; Charlotte Holm
Journal:  Arch Gynecol Obstet       Date:  2022-09-15       Impact factor: 2.493

2.  Development of a core outcome set for studies on prevention and management of pregnancy-associated venous thromboembolism (COSPVenTE): a study protocol.

Authors:  Alexandria King; Rohan D'Souza; Lizabeth Teshler; Nadine Shehata; Ann K Malinowski
Journal:  BMJ Open       Date:  2020-07-19       Impact factor: 2.692

3.  The use of intravenous iron in pregnancy: for whom and when? A survey of Australian and New Zealand obstetricians.

Authors:  Sarah Smith-Wade; Giselle Kidson-Gerber; Antonia Shand; Luke Grzeskowiak; Amanda Henry
Journal:  BMC Pregnancy Childbirth       Date:  2020-11-04       Impact factor: 3.007

4.  Intravenous iron isomaltoside versus oral iron supplementation for treatment of iron deficiency in pregnancy: protocol for a randomised, comparative, open-label trial.

Authors:  Veronika Markova; Rebecka Hansen; Lars Lykke Thomsen; Anja Pinborg; Torben Moos; Charlotte Holm
Journal:  Trials       Date:  2020-08-26       Impact factor: 2.279

Review 5.  Maternal Iron Status in Pregnancy and Child Health Outcomes after Birth: A Systematic Review and Meta-Analysis.

Authors:  Hugo G Quezada-Pinedo; Florian Cassel; Liesbeth Duijts; Martina U Muckenthaler; Max Gassmann; Vincent W V Jaddoe; Irwin K M Reiss; Marijn J Vermeulen
Journal:  Nutrients       Date:  2021-06-28       Impact factor: 5.717

6.  Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis.

Authors:  Ewelina Rogozińska; Jahnavi Daru; Marios Nicolaides; Carmen Amezcua-Prieto; Susan Robinson; Rui Wang; Peter J Godolphin; Carlos Martín Saborido; Javier Zamora; Khalid S Khan; Shakila Thangaratinam
Journal:  Lancet Haematol       Date:  2021-07       Impact factor: 18.959

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.